Hyperthermia has been used in many cancer clinics
in Europe with interesting results, 50% of cancer
patients use alternative/complementary methods. Companies
such as CELN and BIOMF BZYR will have wide acceptance
if the clinical results are adequate with off label
use. Hyperthermia is already advocated with many
alternative/complementary health professionals. Bzyr will present their
recent data on three phase III trial in Brain Cancer to
the FDA this year.
Thanks, will look into it in details. Not too
excited by a quick look at the rationals, too many
uncertainities, the end product will need to be very selective in
blocking angiogenesis, but definitely worthwhile to
Bonz not a new product, no innovation, but on the
market already small volume, limited market will like to
jump on board if they go in other directions
injury, dental products)
Clpa a lot of smoke because
of a patent (did not read the scientific papers) if
they have selective cellular apoptose this is good but
I will buy back when it is lower and after I
understand their paper(I am not an expert but a Medical
Tu parles Francais?
Be patient and vigilant.
Some of those
companies take a long time to turn a profit (and some will
not) but you can cash along the way.
I am confident
about the fact that NBIX has some good science for
Brain tumors. I bought another company BZYR in 1989
between 9 and 12 cents sold 2 years ago half at 0.40
cents the stock is back at 14 with a bunch of clinical
trials but no product on the market. Another one to
watch is BIOMF had a fit recently and is back around 3.
My strategy is to invest in 10 companies and
Any suggestions for other Biotech that you follow is